The strongest relationship was found in CE CT of CRC patients, where the mutation signature KRAS/BRAF/NRAS was significantly associated with three GLCM features (energy, maximum probability and sum average), achieving a final AUC of 0.829 on an internal validation cohort [106]. This evidence concerns the gene NRAS and colorectal carcinoma.